MoonLake Immunotherapeutics Quarterly Debt-to-equity in % from Q3 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
MoonLake Immunotherapeutics quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2024.
  • MoonLake Immunotherapeutics Debt-to-equity for the quarter ending September 30, 2024 was 3.05 %, a 9.51% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 3.05 -0.32 -9.51% Sep 30, 2024
Q2 2024 2.53 -2.08 -45.2% Jun 30, 2024
Q1 2024 2.2 -10 -82% Mar 31, 2024
Q4 2023 2.67 -114 -97.7% Dec 31, 2023
Q3 2023 3.37 -178 -98.1% Sep 30, 2023
Q2 2023 4.61 -329 -98.6% Jun 30, 2023
Q1 2023 12.2 -1.83K -99.3% Mar 31, 2023
Q4 2022 117 +370 Dec 31, 2022
Q3 2022 181 +554 Sep 30, 2022
Q2 2022 333 Jun 30, 2022
Q1 2022 1.85K Mar 31, 2022
Q4 2021 -253 Dec 31, 2021
Q3 2021 -373 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.